Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus ZMAX.
PEDIAMYCIN 400 vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
400 mg orally every 6 hours for 10 days.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic